11月11日,诺瓦瓦克斯医药(NVAX)盘中大涨15.94%,引发市场关注。这与美国食品药品监督管理局(FDA)最新决定密切相关。
此前,FDA曾因一些临床试验参与者出现不良反应,暂时叫停了诺瓦瓦克斯新冠流感联合疫苗和独立流感疫苗的后期试验。但诺瓦瓦克斯随后向FDA提供补充材料,证明那些不良反应系参与者原有病症所致,与试验疫苗无关。
经过评估,FDA最终解除了对诺瓦瓦克斯疫苗临床试验的限制。这一决定意味着该公司的这两款疫苗研发项目将重新复苏,为未来商业化推广扫清了障碍。作为新冠疫苗领域的后起之秀,诺瓦瓦克斯备受投资者关注。FDA的最新利好消息重振了市场对公司前景的信心,推动股价出现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.